Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 51
Filter
1.
Eur J Med Res ; 16(8): 367-74, 2011 Aug 08.
Article in English | MEDLINE | ID: mdl-21813379

ABSTRACT

OBJECTIVE: Atherosclerosis is a chronic inflammatory process. Poly(ADP-ribose) polymerase-1 (PARP), a nuclear enzyme linked to DNA repair, has been shown to be involved in atherogenesis; however, the effects on dendritic cells, T cells and serum auto-antibody levels are not fully understood. METHODS: Male Apoe-/- mice on a western diet were treated with the PARP inhibitor INO-1001 (n = 15), while the control group (n = 15) received 5% glucose solution for 10 weeks. RESULTS: Inhibition of PARP markedly reduced atherosclerotic lesion development (p = 0.001). Immunohistochemistry and mRNA analysis revealed a reduced inflammatory compound inside the lesion. Focusing on dendritic cells, INO-1001 reduced number of cells (p = 0.04), grade of activation, represented by Il12 (p = 0.04) and Cd83 (p = 0.03), and grade of attraction, represented by Mip3α (p = 0.02) in the plaque. Furthermore, INO-1001 decreased number of T lymphocyte (p = 0.003) in the lesion and grade of activation after stimulation with oxLDL in vitro. Moreover, serum IgM antibody levels to oxLDL were significantly lower in INO-1001 treated mice (p = 0.03). CONCLUSIONS: Functional blockade of PARP by INO-1001 reduces atherosclerotic lesion development. The anti-atherogenic effect is beside already known mechanisms also moderated due to modulation of DC and T cell invasion and activation, DC attraction as well as IgM antibody levels to oxLDL.


Subject(s)
Atherosclerosis/enzymology , Autoantibodies/chemistry , Dendritic Cells/enzymology , Poly(ADP-ribose) Polymerase Inhibitors , T-Lymphocytes/enzymology , Animals , Apolipoproteins E/genetics , Atherosclerosis/genetics , Atherosclerosis/metabolism , DNA Repair , Dendritic Cells/cytology , Immunohistochemistry/methods , Inflammation , Lipoproteins, LDL/metabolism , Male , Mice , Mice, Knockout , Mice, Transgenic , Poly(ADP-ribose) Polymerases/genetics , RNA/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Spleen/metabolism , T-Lymphocytes/metabolism
2.
Transplant Proc ; 43(5): 1862-7, 2011 Jun.
Article in English | MEDLINE | ID: mdl-21693290

ABSTRACT

BACKGROUND: Calcineurin inhibitor (CNI)-free immunosuppression is used increasingly after heart transplantation to avoid CNI toxicity, but in the absence of a randomized trial, concerns remain over an increased rejection risk. METHODS: We studied the incidence of graft rejection episodes among all cardiac graft recipients, beginning with the first introduction of CNI-free protocols. We compared events during CNI-free and CNI-containing immunosuppression among 231 transplant recipients of overall mean age 55.2 ± 11.8 years, from a mean 5.2 ± 5.4 years after transplantation through a mean follow-up of 3.1 ± 1.4 years. We considered as acute rejection episodes requiring treatment those of International Society for Heart and Lung Transplantation. RESULTS: During the total follow-up of 685 patient years (CNI-containing, 563; CNI-free, 122), we performed 1,374 biopsies which diagnosed 78 rejection episodes. More biopsies were performed in CNI-free patients: biopsies/patient-month of CNI-containing, 0.13 versus CNI-free, 0.22 (P < .05). The incidence of rejection episodes per patient-month was significantly higher on CNI-free compared with CNI therapy, among patients switched both early and later after heart transplantation, namely, within 1 year, 0.119 versus 0.035 (P = .02); beyond 1 year, 0.011 versus 0.004 (P = .007); beyond 2 years, 0.007 versus 0.003 (P = .04); and beyond 5 years: 0.00578 versus 0.00173 (P = .04). CONCLUSIONS: Rejection incidence during CNI-free immunosuppression protocols after heart transplantation was significantly increased in both early and later postoperative periods. Given the potentially long delay to rejection occurrence, patients should be monitored closely for several months after a switch to CNI-free immunosuppressive protocols.


Subject(s)
Calcineurin Inhibitors , Graft Rejection/epidemiology , Heart Transplantation , Immunosuppressive Agents/therapeutic use , Adult , Aged , Cause of Death , Female , Humans , Immunosuppressive Agents/administration & dosage , Incidence , Male , Middle Aged , Retrospective Studies , Survival Analysis
3.
Transplant Proc ; 42(10): 4238-42, 2010 Dec.
Article in English | MEDLINE | ID: mdl-21168673

ABSTRACT

BACKGROUND: Modified release tacrolimus (TAC) is a new, once-daily oral formulation of the established immunosuppressive agent TAC. Simplification of regimen has been associated with better adherence. This study evaluated patient adherence, as well as safety and efficacy among chronic stable heart transplantation (HT) patients switched from a conventional twice daily calcineurin inhibitor-based regimen (TAC or cyclosporine A [CsA]) to (once daily) modified release TAC. METHODS: We switched 54 chronic stable patients (41 males and 13 females) from twice daily dosing with conventional TAC or CsA to once daily dosing with modified release TAC. Self-reported adherence was assessed at baseline and at 4 months after the switch using the Basel Assessment of Adherence with Immunosuppressive Medication Scale [BAASIS]), a 4-item validated questionnaire including also a Visual Analogue Scale (VAS). Nonadherence was defined as any self-reported nonadherence on any item. RESULTS: Modified release TAC was discontinued in 4 patients because of diarrhea (n = 1) or gastrointestinal discomfort (n = 3) leaving 50 evaluable patients. Overall nonadherence at baseline for any of the 4 items was 74% versus 38% after 4 months (P = .0001). Thereafter, adherence improved in 28 patients (56.0%), was unchanged in 18 (36.0%), and decreased in 4 subjects (8.0%). The VAS score improved from 82.3% ± 2.6% to 97.5% ± 4.8% (P < .0001). No significant changes were observed after 4 months regarding hematologic, renal, or liver function parameters (all P = NS). CONCLUSIONS: Therapeutic regimens for transplant recipients are often complex, contributing to a high incidence of medication nonadherence. This study in chronic, stable, heart transplantation patients demonstrated a significant improvement in patient adherence after a switch to modified release TAC, which was generally well tolerated.


Subject(s)
Calcineurin Inhibitors , Cyclosporine/administration & dosage , Heart Transplantation , Immunosuppressive Agents/administration & dosage , Patient Compliance , Tacrolimus/administration & dosage , Adult , Cyclosporine/adverse effects , Cyclosporine/pharmacology , Drug Administration Schedule , Female , Humans , Immunosuppressive Agents/adverse effects , Male , Middle Aged , Tacrolimus/adverse effects
4.
Transplant Proc ; 42(9): 3694-9, 2010 Nov.
Article in English | MEDLINE | ID: mdl-21094840

ABSTRACT

The objectives of the present study were to evaluate the incidence of malignancies and to describe the effects of immunosuppression on survival and recurrence of malignancies after heart transplantation (HTX). Data were analyzed in 211 cardiac allograft recipients, in whom HTX was performed between 1989 and 2005. All of these patients survived for more than 2 years after HTX and received induction therapy with antithymocyte globulin (RATG) guided by T-cell monitoring since 1994. An immunosuppressive regimen consisting of cyclosporine A (CsA) combined with azathioprine was followed by CsA and mycophenolate mofetil (MMF) in 2001; mammalian target of rapamycin (mTOR) inhibitors (everolimus/sirolimus) were used since 2003. Mean patient age at HTX was 51.4 ± 10.5 years; mean follow-up time after HTX 9.2 ± 4.7 years. Overall incidence of neoplasias was 30.8%. Individual risk factors associated with a higher risk of malignancy after HTX were higher age at transplantation (P = .003), male gender (P = .005) and ischemic cardiomyopathy before HTX (P = .04). Administration of azathioprine (P < .0001) or a calcineurin inhibitor (CNI) (P = .02) for more than 1 year was associated with development of malignancy, whereas significantly fewer malignancies were noticed in patients receiving an mTOR-inhibitor (P < .0001). Kaplan-Meier analysis demonstrated a strong statistical trend toward an improved survival in patients with a noncutaneous neoplasia switched to a CNI-free protocol (P = .05). This study demonstrated the impact of a variety of individual risk factors and immunosuppressive drugs on development of malignancy after HTX. Markedly fewer patients with noncutaneous malignancies died after switch to a CNI-free regimen, not quite reaching statistical significance by Kaplan-Meier analysis, however.


Subject(s)
Azathioprine/administration & dosage , Calcineurin Inhibitors , Cyclosporine/administration & dosage , Heart Transplantation/adverse effects , Immunosuppressive Agents/administration & dosage , Neoplasms/etiology , Adolescent , Adult , Azathioprine/adverse effects , Cyclosporine/adverse effects , Drug Therapy, Combination , Everolimus , Female , Germany , Heart Transplantation/mortality , Humans , Immunosuppressive Agents/adverse effects , Incidence , Kaplan-Meier Estimate , Male , Middle Aged , Mycophenolic Acid/administration & dosage , Mycophenolic Acid/analogs & derivatives , Neoplasms/mortality , Proportional Hazards Models , Retrospective Studies , Risk Assessment , Risk Factors , Sirolimus/administration & dosage , Sirolimus/analogs & derivatives , Skin Neoplasms/etiology , Survival Rate , TOR Serine-Threonine Kinases/antagonists & inhibitors , Time Factors , Transplantation, Homologous , Treatment Outcome , Young Adult
5.
Am J Transplant ; 9(11): 2587-96, 2009 Nov.
Article in English | MEDLINE | ID: mdl-19843034

ABSTRACT

The aim of our study was to investigate the ability of Strain-Encoded magnetic resonance imaging (MRI) to detect cardiac allograft vasculopathy (CAV) in heart transplantation (HTx)-recipients. In consecutive subjects (n = 69), who underwent cardiac catheterization, MRI was performed for quantification of myocardial strain and perfusion reserve. Based on angiographic findings subjects were classified: group A including patients with normal vessels; group B, patients with stenosis <50%; and group C, patients with severe CAV (stenosis >or= 50%). Significant correlations were observed between myocardial perfusion reserve with peak systolic strain (r =-0.53, p < 0.001) and with mean diastolic strain rate (r = 0.82, p < 0.001). Peak systolic strain and strain rate were significantly reduced only in group C, while mean diastolic strain rate and myocardial perfusion reserve were already reduced in group B and A. Myocardial perfusion reserve and mean diastolic strain rate had higher accuracy for the detection of CAV (AUC = 0.95, 95% CI = 0.87-0.99 and AUC = 0.93, 95% CI = 0.84-0.98, respectively) and followed peak systolic strain and strain rate (AUC = 0.80, 95% CI = 0.69-0.89 and AUC = 0.78, 95% CI = 0.67-0.87, respectively). Besides the quantification of myocardial perfusion, the estimation of the diastolic strain rate is a useful parameter for CAV assessment. In combination with the clinical evaluation, these parameters may be effective tools for the routine surveillance of HTx-recipients.


Subject(s)
Coronary Artery Disease/pathology , Coronary Circulation , Heart Transplantation , Magnetic Resonance Imaging/methods , Adult , Aged , Chronic Disease , Coronary Angiography , Coronary Artery Disease/diagnostic imaging , Coronary Artery Disease/physiopathology , Diastole , Exercise Test , Female , Graft Survival , Humans , Male , Middle Aged , Postoperative Complications/diagnostic imaging , Postoperative Complications/pathology , Postoperative Complications/physiopathology , Systole , Transplantation, Homologous , Young Adult
6.
Pathologe ; 30(3): 212-8, 2009 May.
Article in German | MEDLINE | ID: mdl-19357849

ABSTRACT

Cardiac amyloidoses are a heterogeneous group of cardiomyopathies that are resistant to treatment and are associated with a poor outcome. Standard heart failure treatment is usually not well tolerated and the underlying disease remains unaffected. The clinical picture is uncharacteristic. Cardiac amyloidosis is often associated with dysfunction of additional organs. Early cardiac amyloid involvement usually reveals left ventricular hypertrophy, impairment of longitudinal shortening and diastolic ventricular function. Without adequate therapy (bi-)ventricular hypertrophy will progress to severe systolic ventricular function decrease. The combination of low voltage pattern, left ventricular hypertrophy and granular sparkling is characteristic for advanced cardiac amyloid involvement. Cardiac magnetic resonance imaging and scintigraphy yield further information on the pattern and severity of cardiac involvement. In unclear cases (left ventricular) endomyocardial biopsy is necessary. Detection of early cardiac involvement and proper identification of patients at high risk for sudden cardiac death due to rapid progressive amyloidosis is still incompletely defined. Referral to specialized centers is strongly recommended.


Subject(s)
Amyloidosis/pathology , Cardiomyopathies/pathology , Algorithms , Amyloid/analysis , Amyloidosis/classification , Amyloidosis/therapy , Biopsy , Cardiomyopathies/therapy , Death, Sudden, Cardiac/pathology , Defibrillators, Implantable , Diagnosis, Differential , Diphosphonates , Echocardiography , Endocardium/pathology , Heart Failure/pathology , Heart Failure/therapy , Heart Transplantation , Humans , Hypertrophy, Left Ventricular/pathology , Hypertrophy, Left Ventricular/therapy , Magnetic Resonance Imaging , Myocardial Contraction/physiology , Myocardium/pathology , Prognosis , Technetium Compounds , Tomography, Emission-Computed, Single-Photon
7.
Eur J Med Res ; 14(4): 147-56, 2009 Apr 16.
Article in English | MEDLINE | ID: mdl-19380287

ABSTRACT

OBJECTIVE: LIGHT (TNFSF 14) belongs to the tumor necrosis factor superfamily and is expressed by activated T cells as well as various types of antigen presenting cells. LIGHT binds to its cellular receptors TR2 and LTbetaR and has a co-stimulatory role in T cell activation. Here, we compared the relative expression of LIGHT in different immune cells and the biological activity of immune cell-derived LIGHT on endothelial cells. METHODS AND RESULTS: Surface expression of LIGHT and mRNA production by PBMC and isolated T cells (CD4+ or CD8+) significantly increased after stimulation with PMA (Phorbolester-12- Myristat-13-Acetat)+ionomycin. No LIGHT expression on PMA stimulated monocytes or monocytic-like THP-1 cells could be detected; differentiation of monocytes and THP-1 cells into macrophages, however, resulted in up-regulation of LIGHT. Supernatants of stimulated T cells contained higher concentrations of soluble LIGHT than macrophage supernatants normalized to cell numbers; release of soluble LIGHT was found to be dependent on metalloproteinase activity. Size determination of released soluble LIGHT by size exclusion chromatography revealed a molecular mass of approximately 60 kDa, suggesting a trimeric form. Released soluble LIGHT induced expression of proinflammatory antigens ICAM-1, tissue factor and IL-8 in human endothelial cells and caused apoptosis of IFN-g pretreated endothelial cells. Soluble LIGHT was detected at low levels in sera of healthy controls and was significantly enhanced in sera of patients with chronic hepatitis C and rheumatoid arthritis (24.93+/-9.41 vs. 129.53+/-49.14 and 172.13+/-77.64; p<0.0005). CONCLUSION: These findings suggest that among immune cells activated T lymphocytes are the main source of soluble LIGHT with released amounts of soluble LIGHT markedly higher compared to platelets. Immune cell-derived membrane-bound and soluble trimeric LIGHT is biologically active, inducing proinflammatory changes in endothelial cells. Enhanced plasma levels of soluble LIGHT in patients with chronic infections suggest a role of LIGHT in systemic inflammatory activation.


Subject(s)
Endothelium, Vascular/metabolism , Leukocytes, Mononuclear/immunology , Macrophages/immunology , T-Lymphocytes/immunology , Tumor Necrosis Factor Ligand Superfamily Member 14/metabolism , Adolescent , Adult , Aged , Arthritis, Rheumatoid/blood , Cell Differentiation , Cells, Cultured , Drug Combinations , Endothelium, Vascular/drug effects , Enzyme-Linked Immunosorbent Assay , Female , Gene Expression/drug effects , Hepatitis C, Chronic/blood , Humans , Intercellular Adhesion Molecule-1/metabolism , Interleukin-8/metabolism , Ionomycin/pharmacology , Leukocytes, Mononuclear/drug effects , Macrophages/drug effects , Middle Aged , Molecular Weight , RNA, Messenger/metabolism , T-Lymphocytes/drug effects , Tetradecanoylphorbol Acetate/pharmacology , Thromboplastin/metabolism , Tumor Necrosis Factor Ligand Superfamily Member 14/blood , Tumor Necrosis Factor Ligand Superfamily Member 14/genetics , Umbilical Veins/cytology , Up-Regulation , Young Adult
8.
Rofo ; 180(7): 639-45, 2008 Jul.
Article in German | MEDLINE | ID: mdl-18561066

ABSTRACT

PURPOSE: Since limited data is available using MR imaging in cardiac amyloidosis, the purpose of our study was to evaluate morphological and functional differences of the heart using cardiac MRI. MATERIALS AND METHODS: 19 consecutive patients (14 males, 5 females, mean age 59 +/- 6 years) with histologically proven cardiac amyloidosis were evaluated with MRI at 1.5 T. Results were compared with data of 10 healthy, age-matched control subjects (5 males, 5 females, mean age 60 +/- 6 years). Functional and morphological data including late enhancement (LE) was acquired. RESULTS: Compared to the control group, patients with cardiac amyloidosis had thickened atrial walls and dilated atriums. Both ventricles and the interventricular septum were thickened. The LV hypertrophy was focal in 11 / 19 (58 %) and global in 4 / 19 (21 %) of patients. A myocardial edema occurred in 2 / 19 patients with cardiac amyloidosis (11 %). An edema of the myocardium was visible in 2 / 19 (11 %) of patients. The LV ejection fraction was statistically significantly decreased. The prevalence of LE was 74 % (14 / 19 of patients). LE was detected predominantly in the LV anterior wall and in the interventricular septum. Within the segments LE was located predominantly in a subendocardial location. Between patients with and without LE no statistically significant differences of functional and morphological results were able to be established. CONCLUSION: There are three major outcomes of our assessment: 1. The LV hypertrophy is focal in the majority of patients with cardiac amyloidosis. 2. No statistically significant differences can be established in regard to the functional and morphological features between patients with and without LE. 3. Myocardial edema is a possible feature in cardiac amyloidosis.


Subject(s)
Amyloidosis/etiology , Amyloidosis/pathology , Cardiomyopathies/etiology , Cardiomyopathies/pathology , Hypertrophy, Left Ventricular/etiology , Hypertrophy, Left Ventricular/pathology , Magnetic Resonance Imaging/methods , Female , Humans , Image Enhancement/methods , Male , Middle Aged , Reproducibility of Results , Sensitivity and Specificity
9.
Transplant Proc ; 40(4): 943-6, 2008 May.
Article in English | MEDLINE | ID: mdl-18555085

ABSTRACT

OBJECTIVE: Acute rejection may lead to cell death following heart transplantation. Programmed cell death (apoptosis) has been described as a cofactor for cell loss in cardiac tissue. The aim of our study was to quantify the amount and extent of apoptotic cells during acute rejection episodes after orthotopic heart transplantation. PATIENTS AND METHODS: Right ventricular biopsies from 27 heart transplant recipients were classified histologically according to rejection grade. Formalin-fixed sections were processed for immunohistochemistry. TUNEL-positive cells were counted and the expression of apoptosis-modulating factors Bax, Bcl-x(L), Bcl-2, and Ki-67 (proliferation marker) was scored. P

Subject(s)
Apoptosis , Graft Rejection/pathology , Heart Transplantation/pathology , Heart Ventricles/pathology , Cell Death , Cell Division , Heart Transplantation/immunology , Humans , In Situ Nick-End Labeling , Myocytes, Cardiac/pathology , Ventricular Function, Right
10.
Transplant Proc ; 40(4): 947-50, 2008 May.
Article in English | MEDLINE | ID: mdl-18555086

ABSTRACT

BACKGROUND: Infections and rejections play key roles in morbidity and mortality in the early postoperative period after orthotopic heart transplantation (HTX). The aim of this study was to evaluate whether qualitative and quantitative analyses of various interstitial leukocytes in endomyocardial biopsies during the first 2 weeks after HTX provided early information on these complications. PATIENTS AND METHODS: During and after HTX, endomyocardial biopsies were obtained in 51 patients. By immunohistochemistry we determined the CD3-, CD4-, CD8-, CD15-, CD20-, CD57-, and CD68-positive cell numbers projected to planimetrically measured areas. To compare morbidity in the postoperative course, the patients were subdivided into complicated versus uncomplicated after 3 months. RESULTS: In the uncomplicated group, the cell counts of CD3-, CD8-, CD57-, and CD68-positive cells were significantly lower than in the complicated group. CD3-, CD4-, and CD8-positive cell numbers showed a significant decrease in the first week among the uncomplicated group. In the complicated group, the cell counts increased significantly in the second week. The numbers of CD57-positive cells were significantly lower during the first and second weeks among the uncomplicated group. CONCLUSIONS: Increased T lymphocytes, natural killer cells, and macrophages observed in the second week after HTX indicated increased morbidity. A reduction in CD3-positive cells in the first week indicated a low morbidity risk; an increase indicated a higher risk.


Subject(s)
Heart Transplantation/pathology , Heart Ventricles/pathology , Leukocytes/pathology , Myocardium/pathology , Postoperative Complications/pathology , Ventricular Function, Right , Adolescent , Adult , Aged , Antigens, CD/analysis , Biopsy , CD3 Complex/analysis , Female , Humans , Immunohistochemistry , Male , Middle Aged , Postoperative Period
11.
Transplant Proc ; 39(2): 554-7, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17362780

ABSTRACT

BACKGROUND: Platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) seem to play a key role in immunological reactions shortly after heart transplantation (HTx). The aim of this study was to analyze the time course of the expression of PDGF A and B, PDGF-receptor alpha (PDGF-Ralpha) and beta, aFGF, and bFGF on formalin-fixed routine endomyocardial biopsies. PATIENTS AND METHODS: Right ventricular endomyocardial biopsies were obtained from 36 heart transplant recipients up to 2 weeks after HTx. According to the clinical course in the first postoperative year, 3 groups were formed: (1) clinically uneventful course (n = 12); (2) cardiac/systemic infections (n = 12); (3) acute rejection (n = 12). The growth factor expression was examined immunohistochemically. RESULTS: In the early phase after HTx, PDGF A, PDGF B, PDGF-Ralpha, and PDGF-Rbeta were predominantly expressed in endothelial cells. The main expression of PDGF-Ralpha and bFGF was found in cardiomyocytes, endothelial cells, and smooth muscle cells. During the first 2 postoperative weeks, PDGF A, PDGF B, and PDGF-Rbeta showed a similar time course of expression: A significantly elevated expression in the first week was followed by a decrease in the second week. In the rejection group, PDGF A was significantly elevated after the first week. CONCLUSIONS: The increased expression of PDGF in the first postoperative week can be interpreted as an unspecific reaction to peritransplant injury. The prolonged expression of PDGF A, PDGF B, and PDGF-Rbeta showed that there were ongoing immunological reactions in the transplant during week 2. The persistence of elevated PDGF A expression might be of prognostic value in terms of a risk factor for either infection or rejection.


Subject(s)
Growth Substances/analysis , Heart Transplantation/physiology , Adult , Drug Therapy, Combination , Female , Fibroblast Growth Factors/analysis , Graft Rejection/pathology , Heart Transplantation/pathology , Humans , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Platelet-Derived Growth Factor/analysis , Postoperative Period , Transplantation, Homologous , Ventricular Function
13.
Thorac Cardiovasc Surg ; 54(6): 414-7, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16967379

ABSTRACT

OBJECTIVE: The Eurotransplant High-Urgency (HU) Heart Transplantation Program allows urgent heart transplants to be carried out in rapidly deteriorating patients with acute-to-chronic heart failure on the elective waiting list. But do the results of HU heart transplantation justify performing primary heart transplantation in these critically ill patients and offer an acceptable outcome? METHODS: Between 2000 and 2004, 64 heart transplantations (HTx) (32 elective and 32 HU-HTx) were performed in our department. After having been accepted in an auditing process based on HU criteria, intensive care patients in NYHA functional class IV (cardiac index 1.7 l/min/qm BS), in end-organ failure (creatinine 1.5 mg/dl), and with catecholamine dependence (dobutamine 8 microg/kg/min), are given priority with respect to organ allocation, and their data were compared to data from elective patients from the same period. RESULTS: HU requests were accepted in 97 % of cases. Two requests were not accepted, and both patients with contraindications for assist device implantation died within one week. The HU patients were 100 % in NYHA class IV, 93 % of the elective patients were in NYHA class III. Waiting time on the HU list was 13 days, and 7 of these patients died before HTx. Following heart transplantation, survival rates at 30 days and at one year of the HU group were 88 % and 85 % versus 94 % and 93 % in the elective group. CONCLUSIONS: This study shows that end-stage heart failure patients in the HU program can be transplanted primarily with good results if an organ is available in time. We are still in the position where the HU program only manages the organ shortage; there are still too many patients on the waiting list who die before receiving a donor organ.


Subject(s)
Heart Failure/surgery , Heart Transplantation , Outcome Assessment, Health Care , Patient Selection , Acute Disease , Adult , Emergencies , Europe , Female , Germany , Health Care Rationing , Humans , Male , Medical Audit , Middle Aged , Survival Analysis , Waiting Lists
15.
Am J Transplant ; 6(11): 2750-8, 2006 Nov.
Article in English | MEDLINE | ID: mdl-16939514

ABSTRACT

Renal failure is a major cause of morbidity after heart transplantation. It is unclear whether calcineurin inhibitor (CNI) free immunosuppression provides more nephroprotection than low-dose CNI therapy. Thirty-nine patients with renal failure on low-dose cyclosporine A (CsA) were studied (62.9 +/- 8.7 years, five female, 8.2 +/- 4.3 years posttransplant, serum creatinine: 1.9 +/- 0.3 mg/dL, calculated GFR (cGFR): 48.2 +/- 18.3 mL/min, CsA C0 level: 64.0 +/- 19.9 ng/mL). All patients had been treated with low-dose CsA >6 months, renal function was stable or slowly decreasing (creatinine 1.7-3.5 mg/dL). Nineteen patients were randomized to discontinuation of CsA and overlapping rapamycin therapy initiation (RAPA), 20 patients continued low-dose CsA (control). Three patients (16%) discontinued rapamycin medication for side effects (diarrhea, skin rash), two patients developed pneumonia and pulmonary embolism, respectively, no rejection or other infectious complications were seen. After 6 months, renal function in the control group was unchanged. In the RAPA group, renal function markedly improved (creatinine: 2.08 +/- 0.15 to 1.67 +/- 0.13 mg/dL, cGFR: 48.5 +/- 21.4 to 61.7 +/- 21.4 mL/min (p < 0.001 within and between groups)). In carefully selected late survivors following heart transplantation who are at low risk of rejection, CNI-free rapamycin-based immunosuppression improves cGFR even in those already receiving low-dose CsA therapy. The results of this study warrant further confirmation in larger clinical trials that are powered to assess clinical outcomes.


Subject(s)
Cyclosporine/administration & dosage , Heart Transplantation/immunology , Kidney Function Tests , Sirolimus/therapeutic use , Adult , Aged , Blood Pressure/drug effects , Cholesterol/blood , Dose-Response Relationship, Drug , Female , Hemoglobins , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Platelet Count , Proteinuria , Triglycerides/blood
16.
Histopathology ; 48(6): 736-47, 2006 May.
Article in English | MEDLINE | ID: mdl-16681691

ABSTRACT

AIMS: To investigate whether or not there are differences in the distribution of extracellular matrix (ECM) proteins and matrix metalloproteinases (MMPs) in end-stage heart failure underlying different cardiomyopathies. METHODS AND RESULTS: Thirty-nine explanted human hearts were investigated: 15 with dilated cardiomyopathy (DCM), 17 with ischaemic cardiomyopathy (ICM) and seven with valvular cardiomyopathy (VCM). Transmural samples from four different sites were investigated. Frozen sections were processed for immunohistochemistry for collagens type I, III, IV, laminin and fibronectin, as well as MMP-1, -2 and -9. Volume densities were determined. All ECM components were expressed more frequently in DCM than in ICM. Comparing ICM with VCM, all proteins were found more frequently in VCM than in ICM except for type III collagen, which was significantly more frequent in ICM. Comparing DCM and VCM, VCM showed significantly higher volume densities for type III collagen and laminin. MMPs showed only slight variations between the cardiomyopathies. CONCLUSION: The distribution of ECM proteins differs between DCM, ICM and VCM, which suggests that they can be morphologically discriminated by interstitial fibrosis, especially by their expression of matrix proteins.


Subject(s)
Extracellular Matrix Proteins/analysis , Matrix Metalloproteinases/analysis , Myocardium/pathology , Adult , Aged , Cardiomyopathy, Dilated/metabolism , Cardiomyopathy, Dilated/pathology , Collagen Type I/analysis , Collagen Type III/analysis , Collagen Type IV/analysis , Female , Fibronectins/analysis , Fibrosis , Heart Valve Diseases/metabolism , Heart Valve Diseases/pathology , Humans , Immunohistochemistry , Laminin/analysis , Male , Matrix Metalloproteinase 1/analysis , Matrix Metalloproteinase 2/analysis , Matrix Metalloproteinase 9/analysis , Middle Aged , Myocardial Ischemia/metabolism , Myocardial Ischemia/pathology , Myocardium/chemistry
17.
Clin Transplant ; 18(5): 513-7, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15344952

ABSTRACT

BACKGROUND: Detection of cardiac allograft rejection is based on the histological examination of endomyocardial biopsies (EMB). We have explored the possibility of whether graft rejection could be detected by characteristic gene expression patterns in peripheral blood mononuclear cells (PBMC) of heart-transplant recipients. METHODS: The study included 58 blood samples of 44 patients. On the day of EMB, mononuclear cells were isolated from peripheral blood, and gene expression was measured by quantitative real-time PCR. Thirty-nine parameters, including cytokine and chemokine genes were analyzed. Gene expression results were correlated with histological assessment of concomitant evaluated EMB according to International Society for Heart and Lung Transplantation (ISHLT) nomenclature. RESULTS: Gene expression of perforin, CD95 ligand, granzyme B, RANTES, CXCR3, COX2, ENA 78 and TGF-beta1 was significantly different in PBMC of patients with mild to moderate degrees of allograft rejection (> or =grade 2) compared with patients exhibiting no or minor forms of rejection ( or =grade 2 vs.

Subject(s)
Graft Rejection/diagnosis , Heart Transplantation , Leukocytes, Mononuclear/metabolism , Polymerase Chain Reaction , Antigens, Surface/genetics , Apoptosis/genetics , Chemokine CCL5/genetics , Chemokine CXCL5 , Chemokines, CXC/genetics , Chemotaxis, Leukocyte/genetics , Cyclooxygenase 2 , Fas Ligand Protein , Female , Gene Expression Regulation/genetics , Graft Rejection/pathology , Granzymes , Humans , Isoenzymes/genetics , Ligands , Male , Membrane Glycoproteins/genetics , Membrane Proteins , Middle Aged , Perforin , Pore Forming Cytotoxic Proteins , Prostaglandin-Endoperoxide Synthases/genetics , Receptors, CXCR3 , Receptors, Chemokine/genetics , Sensitivity and Specificity , Serine Endopeptidases/genetics , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta1 , fas Receptor/genetics
19.
Heart ; 87(6): 520-4, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12010931

ABSTRACT

BACKGROUND: After acute myocardial infarction, the structural protein T is released considerably longer than cytosolic creatine kinase (CK), CK MB isoenzyme (CK-MB), or lactate dehydrogenase (LDH) and late troponin T release (> 48 hours after onset of chest pain) appears to be less affected by early coronary reperfusion. OBJECTIVE: To investigate the precision of a single measurement of circulating troponin T concentrations 72 hours after onset of chest pain compared with standard scintigraphic and enzymatic estimates of myocardial infarct size. METHODS: Quantitative single photon emission computed tomography thallium-201 scintigraphy at rest was performed in 37 patients 2-3 weeks after myocardial infarction (group 1: 14 patients without early coronary reperfusion; group 2: 23 patients with early reperfusion achieved by thrombolytic therapy, by percutaneous transluminal coronary angioplasty, or by both). RESULTS: In both groups, the number of myocardial segments with abnormal thallium-201 uptake indicating the individual extent of irreversible myocardial damage correlated significantly with the troponin T concentrations 72 hours after infarction as well as with peak concentrations of CK, CK-MB, and LDH. CONCLUSION: The data show that a single measurement of circulating troponin T 72 hours after onset of chest pain--independent of reperfusion--is superior for the estimation of myocardial infarct size to measurement of peak CK, CK-MB, or LDH, which require serial determinations and depend on coronary reperfusion.


Subject(s)
Myocardial Infarction/pathology , Troponin T/blood , Adult , Biomarkers/blood , Creatine Kinase/blood , Creatine Kinase, MB Form , Female , Humans , Isoenzymes/blood , Male , Middle Aged , Myocardial Infarction/blood , Myocardial Infarction/diagnostic imaging , Myocardial Revascularization/methods , Sensitivity and Specificity , Thallium Radioisotopes , Thrombolytic Therapy/methods , Time Factors , Tomography, Emission-Computed, Single-Photon/methods
20.
Eur Heart J ; 23(1): 70-8, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11741364

ABSTRACT

AIMS: Elevated plasma levels of proinflammatory cytokines have been reported in patients with congestive heart failure. The purpose of this study was to assess whether cytokines improve risk stratification in a homogeneous group of NYHA class III patients with a left ventricular ejection fraction <40%. METHODS AND RESULTS: Plasma concentrations of big endothelin, tumour necrosis factor alpha, interleukins -1, -6, -10 and -12, sCD14 and GM-CSF were measured by ELISA in 91 NYHA III patients [mean (SD) age: 55 (10) years, 69% male, 34% coronary artery disease, 66% dilated cardiomyopathy] with a left ventricular ejection fraction and a peak oxygen uptake (peak VO2) of 19 (9)% and 12.1 (3.6) ml x min(-1) x kg(-1), respectively. During follow-up [22 (13) months], 31 patients (34%) died due to cardiovascular causes. In non-survivors, interleukin-6 was twice as high as in survivors [12.8 (16.9) pg x ml(-1)vs 5.6(5.3) pg x ml(-1), P<0.003], whereas plasma concentrations of the other cytokines showed no significant differences. Concerning long-term survival (> or =1 year), multivariate Cox regression analysis revealed an independent prognostic power for interleukin-6, which was further improved by combining with left ventricular ejection fraction and peak VO2, while for short-term survival (up to 6 months) interleukin-6 did not allow risk stratification. CONCLUSION: In NYHA class III patients, plasma concentrations of interleukin-6 are predictive of long-term survival. However, its value may be limited for clinical decision-making for cardiac transplantation (short-term survival).


Subject(s)
Cytokines/blood , Aged , Circadian Rhythm/physiology , Female , Follow-Up Studies , Germany/epidemiology , Heart Failure/blood , Heart Failure/diagnosis , Heart Failure/mortality , Humans , Male , Middle Aged , Multivariate Analysis , Oxygen/blood , Predictive Value of Tests , Prognosis , Risk Factors , Severity of Illness Index , Stroke Volume/physiology , Survival Analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...